# Kyparissia Sirinakis

> Kyparissia Sirinakis is a seed investor at Epidarex Capital backing Medical and Therapeutics. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Epidarex Capital](https://shizune.co/investors/profile/epidarex-capital)
- Location: Bethesda, United States
- Total investments: 1
- Last investment: Jan 2021
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/kyparissia-kyp-sirinakis-62700b6/

Kyparissia Sirinakis is a seed investor at Epidarex Capital in Bethesda focused on Medical and Therapeutics. Ms. Sirinakis has more than twenty years of experience and a strong track record as an early-stage investor and senior executive in various health science and technology companies. Prior to co-founding Rock Spring Ventures, Ms. Sirinakis was a senior member of the MLSV management team where she actively managed several MLSV portfolio companies. Ms.Sirinakis was the Founder and Managing Director of WomenAngels.net LLC (“WAN”), a successful early-stage venture focused on the U.S. Mid-Atlantic region. WAN, a fund launched in 2000, generated a highly competitive Internal Rate of Return. WAN's success was driven by investing in highly disruptive technology platforms developed by strong management teams targeting large and unmet market needs. Ms. Sirinakis also has extensive experience working in the university environment as the Director of a technology accelerator and adjunct professor at George Mason University. She was the CFO for Oncologix, a Maryland venture-backed, early-stage biotechnology company which was subsequently sold to Antigenics, Inc. Ms. Sirinakis has held positions on the Board of Directors for numerous start-up companies throughout her career. She is a graduate of Boston College’s School of Management Honours Program and a Certified Public Accountant in the State of Maryland.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 100% |
| Therapeutics | 1 | 100% |
| Biotechnology | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Slate Bio | Slate Bio is an immunotherapeutics development company that develops therapies that restore the body's natural immunological response in different diseases using bifunctional IL233 cytokine, thereby providing users with an independent synergistic pathway that has greater tissue selectivity and improved pharmacodynamics. | $1.8M | Seed | Jan 19, 2021 |  |

1 of 1 investments shown.

## Co-investors
- [Virginia Venture Partners](https://shizune.co/investors/profile/cit-gap-funds) — VC Fund, 1 deal together
- [PharmaDirections](https://shizune.co/investors/profile/pharmadirections) — VC Fund, 1 deal together
- [UVA Licensing & Ventures Group](https://shizune.co/investors/profile/uva-licensing-ventures-group) — VC Fund, 1 deal together
- [VTC Seed Fund](https://shizune.co/investors/profile/vtc-seed-fund) — VC Fund, 1 deal together

## About Epidarex Capital

VC Fund · Bethesda, United States

Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.

5 contacts available at Epidarex Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Elizabeth Roper | Partner | https://shizune.co/investors/profile/elizabeth-roper |
| Peter Finan | Partner | https://shizune.co/investors/profile/peter-finan |
| Terri Burke | Venture Partner | https://shizune.co/investors/profile/terri-burke |
| Kyparissia Sirinakis | Founder & Managing Partner | https://shizune.co/investors/profile/kyparissia-sirinakis |
| Sinclair Dunlop | Managing Partner | https://shizune.co/investors/profile/sinclair-dunlop |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Kyparissia Sirinakis invest in?

Kyparissia Sirinakis invests primarily in Medical, Therapeutics and Biotechnology startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Kyparissia Sirinakis last invest?

The most recent investment recorded for Kyparissia Sirinakis closed in Jan 2021. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co